

00005.001285.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:	)	
	:	Examiner: Sarah Pihonak
HIROSHI KASE ET AL.	)	
	:	Group Art Unit: 1627
Appln. No.: 10/565,239	)	
	:	Conf. No.: 9168
Filed: January 19, 2006	)	
	:	
For: PHARMACEUTICAL COMPOSITION	)	
	:	
U.S. Patent No.: 8,034,820 B2	)	
	:	
Issued: October 11, 2011	)	December 12, 2011

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF CORRECTION  
UNDER RULES 322 AND 323

Sir:

It is respectfully requested that a Certificate of Correction be issued by the Patent and Trademark Office due to errors which appear in the printed patent as a result of Patent and Trademark Office mistakes, and mistakes of a clerical, typographical, or minor character, which were not the fault of the Patent and Trademark Office.

The amount of \$100.00 to cover the statutory fee for such Certificate of Correction is being paid concurrently; please charge any deficiency in the fee, and credit any overpayment, to Deposit Account 06-1205.

Patentees' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Lawrence S. Perry/

Lawrence S. Perry  
Attorney for Patentees  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
Facsimile: (212) 218-2200

FCHS\_WS 7173972v1

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : US 8,034,820 B2  
DATED : October 11, 2011  
INVENTOR(S) : HIROSHI KASE ET AL.

Page 1 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ON THE TITLE PAGE [57] ABSTRACT:

Line 3, “comprises” should read --comprise--.

COLUMN 1:

Line 21, “a treatment” should read --treatment-- and  
“carried out” should read --is carried out--;

Line 35, “38,” should read --38--; and

Line 40, “38,” should read --38--.

COLUMN 3:

Line 36, “drug for” should read --drug ¶ for-- (full margin).

COLUMN 4:

Line 60, “a serotonin” should read --serotonin--.

COLUMN 5:

Line 57, “thyl-3,17-dihydro-” should read --thyl-3,7-dihydro---; and

Line 66, “(52). The” should read --(52) The--.

COLUMN 9:

Line 32, “inhibitor simultaneously” should read --inhibitor ¶ simultaneously-- (full margin); and

Line 56, “drug for” should read --drug ¶ for-- (full margin).

**MAILING ADDRESS OF SENDER:**

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
(212) 218-2100 - Telephone  
(212) 218-2200 – Facsimile

**PATENT NO.:**

US 8,034,820 B2

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : US 8,034,820 B2  
DATED : October 11, 2011  
INVENTOR(S) : HIROSHI KASE ET AL.

Page 2 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

COLUMN 11:

Line 6, "Pubilished" should read --Published--.

COLUMN 18:

Line 50, "mociobemide" should read --moclobemide--.

COLUMN 19:

Line 5, "Psychiatric" should read --psychiatric--.

COLUMN 21:

Line 4, "Immobility" should read --immobility--.

COLUMN 22:

Line 6, "Immobility" should read --immobility--; and  
Line 54, "decrease" should read --decreases--.

COLUMN 25:

Line 18, "Prescription" should be moved to following table, as title; and  
Line 47, "Prescription" should be moved to following table, as title.

COLUMN 26:

Line 9, "Prescription" should be moved to following table, as title;  
Line 37, "Prescription" should be moved to following table, as title; and  
Line 67, "Prescription" should be moved to following table, as title.

**MAILING ADDRESS OF SENDER:**

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
(212) 218-2100 - Telephone  
(212) 218-2200 - Facsimile

**PATENT NO.:**

US 8,034,820 B2

Form PTO/SB/44 (09-07)

FCHS\_WS 7173972 v1

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : US 8,034,820 B2  
DATED : October 11, 2011  
INVENTOR(S) : HIROSHI KASE ET AL.

Page 3 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

COLUMN 27:

Line 28, "Prescription" should be moved to following table, as title; and  
Line 56, "Prescription" should be moved to following table, as title.

COLUMN 28:

Line 10, "blending" should read --blending and--; and  
Line 16, "Prescription" should be moved to following table, as title;  
Ex. 10 Table,

"	Compound (I)	1 mg	"
	Purified soybean oil	200 mg	
	Purified yolk lecithin	24 mg	
	Glycerin for injection	50 mg	
	Distilled water for injection	1.72 mL	
		2.00 mL	

should read

--	Compound (I)	1 mg	--;
	Purified soybean oil	200 mg	
	Purified yolk lecithin	24 mg	
	Glycerin for injection	50 mg	
	Distilled water for injection	1.72 mL	
		2.00 mL	

Line 36, "blending" should read --blending and--;  
Line 42, "Prescription" should be moved to following table, as title;

**MAILING ADDRESS OF SENDER:**

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
(212) 218-2100 - Telephone  
(212) 218-2200 - Facsimile

**PATENT NO.:**

US 8,034,820 B2

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : US 8,034,820 B2  
DATED : October 11, 2011  
INVENTOR(S) : HIROSHI KASE ET AL.

Page 4 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Ex. 11 Table,

“	Bupropion	10 mg	”
	Purified soybean oil	200 mg	
	Purified yolk lecithin	24 mg	
	Glycerin for injection	50 mg	
	Distilled water for injection	1.72 mL	
		2.00 mL	

should read

--	Bupropion	10 mg	--; and
	Purified soybean oil	200 mg	
	Purified yolk lecithin	24 mg	
	Glycerin for injection	50 mg	
	Distilled water for injection	1.72 mL	
		2.00 mL	

Line 64, “blending” should read --blending and--.

COLUMN 29:

Line 4, Prescription” should be moved to following table, as title;

Ex. 12, Table,

“	Compound (I)	2 mg	”
	Clomipramine hydrochloride	25 mg	
	Purified soybean oil	200 mg	
	Purified yolk lecithin	24 mg	
	Glycerin for injection	50 mg	
	Distilled water for injection	1.62 mL	
		2.00 mL	

MAILING ADDRESS OF SENDER:

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
(212) 218-2100 - Telephone  
(212) 218-2200 - Facsimile

PATENT NO.:

US 8,034,820 B2

Form PTO/SB/44 (09-07)

FCHS\_WS 7173972 v1

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : US 8,034,820 B2  
DATED : October 11, 2011  
INVENTOR(S) : HIROSHI KASE ET AL.

Page 5 of 5

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

should read

--	Compound (I)	2 mg	
	Clomipramine hydrochloride	25 mg	
	Purified soybean oil	200 mg	
	Purified yolk lecithin	24 mg	
	Glycerin for injection	50 mg	
	Distilled water for injection	1.62 mL	
		2.00 mL	--;

Line 32, "Prescription" should be moved to following table, as title; and  
Line 46, "provide" should read --provides--.

COLUMN 30:

Line 25, "fluoxetine," should read --fluoxetine--;  
Line 38, "fluoxetine," should read --fluoxetine--; and  
Line 51, "fluoxetine," should read --fluoxetine--.

**MAILING ADDRESS OF SENDER:**

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
(212) 218-2100 - Telephone  
(212) 218-2200 - Facsimile

**PATENT NO.:**

US 8,034,820 B2

Form PTO/SB/44 (09-07)